S-1/A: AtlasClear Holdings Files Amendment for Resale of Up to 77.6 Million Shares
S-1/A Filing
AtlasClear Holdings has filed an amendment to its registration statement for the potential resale of up to 77,577,099 shares of its common stock by selling stockholders.
Summary
- AtlasClear Holdings has filed an amendment to its registration statement for the potential resale of up to 77,577,099 shares of its common stock by selling stockholders.
- These shares consist of merger consideration shares, shares issuable to Wilson-Davis sellers, shares issuable to Pacsquare, shares issued to Commercial Bancorp, shares issuable to Chardan Capital Markets, shares issuable to Funicular Funds, shares issued to Qvent LLC, shares issued to Calabrese Consulting LLC, shares issued to Grant Thornton LLP, shares issued to IB Capital LLC, shares issued to Outside The Box Capital Inc., shares issuable to Carriage House Capital, Inc., shares issuable to Interest Solutions, LLC, shares issuable to JonesTrading Institutional Services LLC, shares issuable to Winston & Strawn LLP, shares issuable to Lead Nectar and shares issuable to Tau Investment Partners LLC.
- The company will not receive any proceeds from the sale of these shares by the selling stockholders.
- As of August 1, 2024, the number of shares of Common Stock that may be offered for resale by the Selling Stockholders pursuant to this prospectus is almost 6.23 times larger than the number of outstanding shares of Common Stock.
- Sales of a substantial number of shares of Common Stock in the public markets, including by the Selling Stockholders, some of whom may obtain their shares at prices or values below the market price per share, or the perception in the market that such sales could occur, could result in a significant decline in the public trading price of the Common Stock.
- Certain Selling Stockholders including holders of founder shares, may experience a positive rate of return on the sale of their shares covered by this prospectus even if the market price per share of Common Stock is below $10.00 per share, while the public stockholders may not experience a similar rate of return on the shares they purchased due to differences in the purchase prices and the trading price.
- As of August 1, 2024, the last sale price of the Common Stock as reported on the NYSE was $0.28 per share.
Sentiment
Score: 3
Explanation: The document presents a mixed picture. While it outlines the potential for selling stockholders to benefit, it also highlights the risk of significant price decline and dilution for existing shareholders. The overall tone is cautious due to the potential negative impact on the stock price.
Positives
- The registration allows the company to fulfill obligations related to previous agreements.
- The company has the potential to receive up to $10 million through the ELOC agreement with Tau Investment Partners LLC.
Negatives
- The potential sale of a large number of shares could significantly decrease the market price of the common stock.
- Existing shareholders may experience dilution.
- Certain selling stockholders may profit even if the share price is below $10.00, while public stockholders may not.
- The company will not receive any proceeds from the resale of shares by the selling stockholders.
Risks
- Future sales, or the perception of future sales, by the Company or its stockholders in the public market could cause the market price for the Common Stock to decline.
- The shares of our Common Stock being registered for resale are anticipated to constitute a considerable percentage of our public float.
- A significant portion of the shares of our Common Stock being registered for resale may be acquired by Selling Stockholders at prices below the current market price of our Common Stock.
- This discrepancy in purchase prices may have an impact on the market perception of our Common Stocks value and could increase the volatility of the market price of our Common Stock or result in a significant decline in the public trading price of our Common Stock.
- The registration of these shares for resale creates the possibility of a significant increase in the supply of our Common Stock in the market.
- The increased supply, coupled with the potential disparity in purchase prices, may lead to heightened selling pressure, which could negatively affect the public trading price of our Common Stock.
Future Outlook
The document does not provide specific forward-looking statements about the company's future financial performance, but it does mention the potential for future sales of common stock and the impact that could have on the market price.
Industry Context
The document does not provide specific industry context beyond the company's own operations and agreements.
Stakeholder Impact
- Shareholders: Potential for dilution and decline in stock price.
- Selling Stockholders: Opportunity to sell shares, potentially at a profit even if the market price is below $10.00.
- Company: No direct financial benefit from the resale of shares, but may be able to raise capital through the ELOC agreement.
Next Steps
- Selling stockholders may offer and sell shares of Common Stock from time to time.
- The Company may need to register additional shares for resale if the estimated number of shares is incorrect.
Key Dates
| Date | Description |
|---|---|
| September 13, 2023 | Date of Marketing Services Agreement between OTB and Quantum. |
| July 31, 2024 | Date of ELOC Agreement between the Company and Tau. |
| August 1, 2024 | Date shares outstanding were calculated; last sale price of Common Stock was $0.28. |
| August 9, 2024 | Date Winston & Strawn may begin receiving shares for legal services. |
Keywords
common stock, resale, selling stockholders, registration statement, AtlasClear Holdings, shares, securities, Funicular, Chardan, Pacsquare, ELOC, Winston & Strawn, JonesTrading, Interest Solutions, Carriage, IB Capital, Grant Thornton, Calabrese, Quantum Ventures, Wilson-Davis
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.